阿苯达唑临床应用的获益及其风险  

Risks and Benefits of Albendazole in Clinical Application

作　　者：朱振国[1] 郑荣远[1] 殷为勇[1] 杨学志[1] 曹立亚[2] 

机构地区：[1]温州医学院附属第一医院浙江省神经药物流行病学研究中心,浙江温州325000 [2]国家食品药品监督管理局药品评价中心

出　　处：《药物流行病学杂志》2008年第3期153-156,共4页Chinese Journal of Pharmacoepidemiology

基　　金：国家食品药品监督管理局药品评价中心资助项目

摘　　要：目的:了解阿苯达唑(ADZ)上市后的临床应用价值及其安全性,评价使用该药的获益及其风险。方法:通过检索CNKI数字图书馆、MEDLINE/PUBMED数据库、解放军医学图书馆等1994～2005年间的相关资料,对所收集的数据信息进行整理、归纳与统计分析。结果:共收集阿苯达唑临床治疗文献190篇。不良反应214例。阿苯达唑可治疗21种人体寄生虫病,有效率70%～99.8%;其常见的一般不良反应有头痛、头晕、腹部不适等,总发生率国内外分别为5.38%、33.53%,严重药物不良反应(serious adverse drug reactions,SADR)有脑病、癫痫、药疹等,发生率分别为1.64%、8.20%、19.67%,结论:阿苯达唑驱虫治疗广谱、高效、临床使用广泛;严重不良反应隐藏着治疗的风险,可致死、致残;应加强ADZ的安全监管,提倡合理用药,保障用药安全。Objective： To observe the clinical application value and safety of albendazole in post-marketing and to evaluate its risk and benefits in clinical application. Method： By searching ＂Caj full-text database＂, Medline/Pubmed database and liberation army medical library from 1994 to 2005, the data and information collected were reviewed. Result： It was found that 190 articles about clinical use of albendazole and 214 cases of serious ADRs （SADR） were reported. Albendazole could treat 21 kinds of human parasitosis and its efficient rate was 70 -99.8%. Its general ADRs were headache, dizziness and abdominal discomfort, etc. and its total incidence rate was 5.38% in China and 33, 53% aboard respectively. SADRs were encephalopathy, seizure and drug eruption, its incidence rates being 1.64%, 8.20% and 19.67% respectively. Conclusion： Albendazole is a helminthicide of broad-spectrum used effectively and widely in the world. SADRs showed some risk in the treatment with albendazole and caused death or mutilation. So safety monitoring and rational use of albendazole should be strengthened and advocated accordingly and the safety of public use of drugs should be guaranteed.

关 键 词：阿苯达唑 临床应用 不良反应 合理用药 

分 类 号：R978.63[医药卫生—药品]